Allergan Inc. producer of the specialty cosmetic product Botox has said that it would file a new-drug application with the U.S. Food and Drug Administration for bimatoprost, which is designed to stimulate eyelash growth.

The company will file a New Drug Application by end of the third quarter of 2008 with the U.S. Food and Drug Administration (FDA) for bimatoprost as a treatment to stimulate eyelash growth. Allergan has completed its clinical trial program demonstrating that its patented formulation of bimatoprost, when applied directly to the base of the eyelashes, results in significant eyelash growth.

Image Courtesy: WSJ

If approved by the FDA for eyelash growth, the company estimates global peak sales of bimatoprost for this indication could exceed $500 million per year. Allergan has exclusive U.S. and foreign patents on the use of bimatoprost and other prostaglandins and prostaglandin analogs as a treatment to stimulate natural eyelash growth.

Marini’s “Age Intervention Eyelash”

Meanwhile, Marini has come up with a new product which is being advertised as a “non-prostaglandin” that gives users the “eyelashes of your dreams.” The “Age Intervention Eyelash” retails at $160. Go get it!

By

Advertisements